secwatch.observer — SEC 8-K summary
======================================

Issuer:     LIFECORE BIOMEDICAL, INC. DE (LFCR)
CIK:        0001005286
Form:       8-K
Filed at:   2026-03-16T23:59:59+00:00
Accession:  0001005286-26-000007
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Lifecore Biomedical reports transition period revenue $75.5M (+20% y/y), Adj. EBITDA $13.1M
--------------------------------------------------------------------------------

- Revenue for seven-month transition period $75.5M, +20% vs prior comparable period; Q4 revenue $35.7M, +10% y/y.
- Net loss for transition period $18.0M, improved from $30.6M; Adjusted EBITDA $13.1M, up from $2.6M.
- Gross margin 31% vs 26%; operating expenses decreased 31% to $24.4M.
- Signed five new programs during transition, including two commercial site transfer programs in Q4.
- Liquidity of $38.9M at quarter end; mid-term target: 12% revenue CAGR, EBITDA margins >25%.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1005286/000100528626000007/0001005286-26-000007-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1005286/000100528626000007/lndc-20260316.htm
  HTML page:      https://secwatch.observer/filing/0001005286-26-000007

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer